Clinical Trial Update: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update reports results of a quadruplet regimen combining daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-07-16